Lobbying registration dated 2026-02-04
Registrant: Cassandra Almeida
Client: Innovative Medicines Canada
Targeted institutions:
Canadian Institutes of Health Research (CIHR)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Global Affairs Canada (GAC)
Canadian International Trade Tribunal (CITT)
Patented Medicine Prices Review Board (PMPRB)
Justice Canada (JC)
House of Commons
Natural Resources Canada (NRCan)
Statistics Canada (StatCan)
Agriculture and Agri-Food Canada (AAFC)
Veterans Affairs Canada (VAC)
National Research Council (NRC)
Canada Revenue Agency (CRA)
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Natural Sciences and Engineering Research Council (NSERC)
Health Canada (HC)
Environment and Climate Change Canada (ECCC)
Prime Minister's Office (PMO)
Fisheries and Oceans Canada (DFO)
Innovation, Science and Economic Development Canada (ISED)
Acts: Patent Act
Food and Drugs Act
Government funding received:
Lobbying activity details:
Proposed pharmacare legislation related to any future national pharmacare program
Free trade treaty agreement as they relate to The Canada-United States-Mexico Agreement (CUSMA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Scientific Research and Experimental Development  (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry